Duvelisib (follicular lymphoma, after ≥ 2 prior therapies)

Subject:

• Active Substance: Duvelisib
• Name: Copiktra^®
• Therapeutic area: Follicular lymphoma
• Pharmaceutical company: Secura Bio Limited

Time table:

• Start: 01.02.2022
• Final decision by G-BA: 21.07.2022

Final decision:

• No additional benefit proved